Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study

The BYOND study evaluated the efficacy and safety of bosutinib 500 mg once daily in patients with chronic myeloid leukemia (CML) resistant/intolerant to prior tyrosine kinase inhibitors (TKIs). These post-hoc analyses assessed the efficacy and safety of bosutinib by resistance or intolerance to prio...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Leukemia research 2024-04, Vol.139, p.107481-107481, Article 107481
Hauptverfasser:	Smith, B. Douglas, Brümmendorf, Tim H., Roboz, Gail J., Gambacorti-Passerini, Carlo, Charbonnier, Aude, Viqueira, Andrea, Leip, Eric, Purcell, Simon, Goldman, Erinn Hoag, Giles, Francis, Ernst, Thomas, Hochhaus, Andreas, Rosti, Gianantonio
Format:	Artikel
Sprache:	eng
Schlagworte:	Aniline Compounds Antineoplastic Agents - adverse effects Bosutinib Chronic myeloid leukemia Dasatinib - adverse effects Humans Imatinib Mesylate - adverse effects Leukemia, Myeloid, Chronic-Phase - drug therapy Nitriles Pathologic Complete Response Philadelphia Chromosome Protein Kinase Inhibitors - adverse effects Pyrimidines Quinolines Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!